Nisa Investment Advisors LLC Has $132,000 Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Nisa Investment Advisors LLC decreased its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 26.4% in the fourth quarter, HoldingsChannel reports. The firm owned 4,450 shares of the medical device company’s stock after selling 1,600 shares during the period. Nisa Investment Advisors LLC’s holdings in Tandem Diabetes Care were worth $132,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. 180 Wealth Advisors LLC acquired a new position in Tandem Diabetes Care in the 4th quarter worth approximately $228,000. International Assets Investment Management LLC boosted its stake in Tandem Diabetes Care by 2,858.2% in the 4th quarter. International Assets Investment Management LLC now owns 4,881 shares of the medical device company’s stock worth $144,000 after purchasing an additional 4,716 shares during the period. Oak Thistle LLC acquired a new position in Tandem Diabetes Care in the 4th quarter worth approximately $540,000. JB Capital LLC boosted its stake in Tandem Diabetes Care by 48.1% in the 4th quarter. JB Capital LLC now owns 24,063 shares of the medical device company’s stock worth $712,000 after purchasing an additional 7,811 shares during the period. Finally, Raymond James & Associates boosted its stake in Tandem Diabetes Care by 128.5% in the 4th quarter. Raymond James & Associates now owns 91,985 shares of the medical device company’s stock worth $2,721,000 after purchasing an additional 51,721 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Citigroup lifted their target price on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. StockNews.com raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday. Finally, Stifel Nicolaus raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and lifted their target price for the company from $24.00 to $37.00 in a research note on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $37.00.

Tandem Diabetes Care Stock Down 1.6 %

Tandem Diabetes Care stock opened at $30.43 on Friday. The company has a market capitalization of $1.96 billion, a P/E ratio of -8.85 and a beta of 1.12. The firm’s fifty day simple moving average is $29.94 and its 200-day simple moving average is $24.86. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91. Tandem Diabetes Care, Inc. has a 1-year low of $13.82 and a 1-year high of $40.92.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. Sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.